Metastatic Cancer Clinical Trials

114 recruitingLast updated: June 17, 2026

There are 114 actively recruiting metastatic cancer clinical trials across 43 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1. Top locations include Houston, Texas, United States, New York, New York, United States, Los Angeles, California, United States. Updated daily from ClinicalTrials.gov.


Metastatic Cancer Trials at a Glance

114 actively recruiting trials for metastatic cancer are listed on ClinicalTrialsFinder across 6 cities in 43 countries. The largest study group is Phase 1 with 44 trials, with the heaviest enrollment activity in Houston, New York, and Los Angeles. Lead sponsors running metastatic cancer studies include Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, and Fudan University.

Browse metastatic cancer trials by phase

Treatments under study

About Metastatic Cancer Clinical Trials

Looking for clinical trials for Metastatic Cancer? There are currently 93 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 114 trials

Recruiting

Evaluating Disparities in Precision Oncology

Metastatic CancerAdvanced Cancer
Indiana University10,600 enrolled1 locationNCT06081517
Recruiting
Phase 3

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Metastatic CancerAdvanced Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc.482 enrolled126 locationsNCT05208047
Recruiting
Phase 2

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Cervical CancerMetastatic CancerAnal Cancer+18 more
Christian Hinrichs20 enrolled3 locationsNCT05686226
Recruiting
Phase 2

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

Metastatic CancerCastrate Sensitive Prostate CancerNeoplasm, Prostate+1 more
Sun Pharmaceutical Industries Limited192 enrolled12 locationsNCT05422911
Recruiting

Immune Resistance Interrogation Study

CancerMetastatic CancerSolid Tumor+1 more
University Health Network, Toronto100 enrolled1 locationNCT04243720
Recruiting
Phase 1

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Triple-Negative Breast CancerPancreatic CancerMelanoma+7 more
Memgen, Inc.40 enrolled2 locationsNCT05076760
Recruiting
Phase 1

Imaging of Solid Tumors Using FAP-2286

Metastatic CancerSolid Tumors, Adult
Thomas Hope191 enrolled1 locationNCT04621435
Recruiting
Phase 1

Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer

Metastatic Cancer
University of Wisconsin, Madison60 enrolled1 locationNCT07197671
Recruiting
Phase 1Phase 2

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerProstate CancerCancer+12 more
Parabilis Medicines, Inc.595 enrolled33 locationsNCT05919264
Recruiting
Phase 2

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

GISTGIST - Gastrointestinal Stromal TumorGastrointestinal Tumors+2 more
Kumquat Biosciences Inc.46 enrolled8 locationsNCT07406633
Recruiting
Phase 1Phase 2

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Advanced Solid TumorNon-small Cell Lung CancerMetastatic Cancer+1 more
Aulos Bioscience, Inc.159 enrolled18 locationsNCT05267626
Recruiting
Not Applicable

FAPI Molecular Imaging for Diagnosis of the CMS4 Unfavorable Colorectal Cancer Subtype

Metastatic Colorectal CancerMetastatic Cancer to Liver
UMC Utrecht45 enrolled1 locationNCT06191120
Recruiting
Phase 2

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Gastric CancerEsophageal AdenocarcinomaMetastatic Cancer+3 more
I-Mab Biopharma US Limited180 enrolled6 locationsNCT07432295
Recruiting
Not Applicable

Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer

Metastatic CancerAdvanced Cancer
Alliance Foundation Trials, LLC.1,000 enrolled7 locationsNCT06963723
Recruiting
Early Phase 1

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

Metastatic CancerHER2Locally Advanced Cancer+2 more
Vanderbilt-Ingram Cancer Center30 enrolled1 locationNCT06828588
Recruiting
Phase 1Phase 2

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Locally AdvancedUnresectableMetastatic Cancers+1 more
Recursion Pharmaceuticals Inc.170 enrolled6 locationsNCT06678659
Recruiting
Phase 2

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

Metastatic Cancer
Memorial Sloan Kettering Cancer Center45 enrolled7 locationsNCT05010031
Recruiting

Prospective Validation of a Points Score System Predicting 30-day Survival

Metastatic Cancer
Indiana University214 enrolled3 locationsNCT05100342
Recruiting

UNC Metastatic Cancer Radiation Therapy Registry

CancerMetastatic Cancer
UNC Lineberger Comprehensive Cancer Center2,000 enrolled1 locationNCT06306924
Recruiting
Phase 2Phase 3

Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers

FatigueMetastatic Cancers
M.D. Anderson Cancer Center240 enrolled1 locationNCT06085716